A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Status:
Completed
Trial end date:
2019-02-19
Target enrollment:
Participant gender:
Summary
The study is a Phase II randomized, open label, multicenter trial designed to identify
whether sirolimus is a potential alternative to prednisone as an up-front treatment for
patients with standard-risk acute GVHD defined according to clinical and biomarker-based risk
stratification. This trial incorporates both a novel up front GVHD therapy (sirolimus) as
well as a novel BMT CTN developed acute GVHD biomarker test.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) National Marrow Donor Program